- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01683370
Pediatric FN Definition 2012 Bern
October 29, 2020 updated by: Dr. Roland Ammann
Pediatric FN Definition 2012 Bern The Impact of Lowering Fever Limits on the Rate of Fever in Chemotherapy-induced Neutropenia (FN). A Prospective Single-center Observational Study in Children and Adolescents With Cancer.
STUDY AIMS Based on prospectively collected information on ear temperatures, ANC values, emergency calls and consultations for fever, and on hospitalizations for FN in children and adolescents with cancer
- to describe the frequency of episodes of FN, and of other clinically relevant FN-related measures
- to compare these frequencies and measures in reality vs. applying Bernese standard limits for defining fever (ear temperature ≥39.0°C)
- to compare these frequencies and measures applying the Bernese standard limit of ≥39.0°C (LimitStandard) vs. a range of hypothetically lower limits defining fever (LimitLow)
- to determine if it would be useful to perform an interventional study on the question of different fever limits, powered to study both efficacy (frequency of FN) and safety (AE in delayed FN diagnosis)
- to use the platform of this prospective study to explore if the serum level of cortisol is associated with adverse events in FN
HYPOTHESIS In children and adolescents with cancer, hypothetically modifying the definitions of fever from ear temperature 39.0°C to lower limits would
- increase the rate of FN episodes diagnosed during chemotherapy (primary endpoint).
- increase the rate of other clinically important FN-related measures related to chemotherapy exposure time (secondary endpoints 1,2,3) and outcome/treatment-related measures during treatment of FN episodes diagnosed in reality (secondary endpoints 4,5,6).
- not relevantly decrease the proportion of FN with AE (secondary endpoint 7).
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
39
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bern, Switzerland, CH-3010
- Division of Hematology/Oncology, Department of Pediatrics, University of Bern / Inselspital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Pediatric patients diagnosed with cancer requiring chemotherapy, treated at the Division of Pediatric Hematology/Oncology, Department of Pediatric, University of Bern / Inselspital, CH-3010 Bern, Switzerland
Description
Inclusion Criteria:
- >1 year and ≤17 years at time of recruitment
- Chemotherapy treatment because of any malignancy for at least 2 months at time of recruitment
- Written informed consent from patients and/or parents for the study
Exclusion Criteria:
- Infants ≤1 year old (reason: differences in standard fever limit and method to measure temperature)
- Denied written informed consent from patients and/or parents for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients
Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate ratio of additional episodes of FN diagnosed (applying LimitLow vs. LimitStandard)
Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of episodes of fever
Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
(Protocol: 1)
|
until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
Rate of emergency calls for fever
Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
(Protocol: 2a)
|
until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
Rate ratio of FN diagnosed earlier (applying LimitLow vs. LimitStandard)
Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
(Protocol: 3)
|
until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
Proportion of FN with blood cultures performed after start of antibiotics (AB) for prolonged fever
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 4a)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Proportion of FN with delayed hospital discharge for prolonged fever
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 5) (Low risk FN episodes with first-day stepping down will be excluded from this analysis.)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Time point of empirical AB switch for prolonged fever during FN
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 6a)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Proportion of FN with any adverse event
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 7a)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Serum level of cortisol
Time Frame: at presentation with FN (in reality)
|
(Protocol: 8)
|
at presentation with FN (in reality)
|
Proportion of FN with switch of empirical AB for prolonged fever
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 4b)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Proportion of FN with add-on of empirical antifungal therapy for prolonged fever
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 4c)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Rate of emergency CBC with consultation for fever
Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
(Protocol: 2b)
|
until 2 weeks after last dose of chemotherapy (expected median, 6 months)
|
Time point of starting empirical antifungal therapy for prolonged fever during FN
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 6b)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Proportion of FN with bacteremia
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 7b)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Proportion of FN with serious medical complication
Time Frame: until end of AB therapy for FN (estimated median, 4 days)
|
(Protocol: 7c)
|
until end of AB therapy for FN (estimated median, 4 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Roland A Ammann, MD, Pediatric Hematology/Oncology, Department of Pediatrics, University of Bern, Bern, Switzerland
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ammann RA, Teuffel O, Agyeman P, Amport N, Leibundgut K. The influence of different fever definitions on the rate of fever in neutropenia diagnosed in children with cancer. PLoS One. 2015 Feb 11;10(2):e0117528. doi: 10.1371/journal.pone.0117528. eCollection 2015.
- Wagner S, Brack EK, Stutz-Grunder E, Agyeman P, Leibundgut K, Teuffel O, Ammann RA. The influence of different fever definitions on diagnostics and treatment after diagnosis of fever in chemotherapy-induced neutropenia in children with cancer. PLoS One. 2018 Feb 20;13(2):e0193227. doi: 10.1371/journal.pone.0193227. eCollection 2018.
- Brack E, Wagner S, Stutz-Grunder E, Agyeman PKA, Ammann RA. Temperatures, diagnostics and treatment in pediatric cancer patients with fever in neutropenia, NCT01683370. Sci Data. 2020 May 26;7(1):156. doi: 10.1038/s41597-020-0504-9.
- Lavieri L, Koenig C, Teuffel O, Agyeman P, Ammann RA. Temperatures and blood counts in pediatric patients treated with chemotherapy for cancer, NCT01683370. Sci Data. 2019 Jul 3;6(1):108. doi: 10.1038/s41597-019-0112-8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
August 31, 2012
First Submitted That Met QC Criteria
September 7, 2012
First Posted (Estimate)
September 11, 2012
Study Record Updates
Last Update Posted (Actual)
November 2, 2020
Last Update Submitted That Met QC Criteria
October 29, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PFND2012B
- KFS-2933-02-2012 (Other Grant/Funding Number: Krebsforschung Schweiz)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fever in Neutropenia
-
Swiss Pediatric Oncology GroupCompletedCancer | Neutropenia | Fever | Pediatrics | Fever in NeutropeniaSwitzerland
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
National Taiwan University HospitalCompleted
-
The University of Hong KongQueen Mary Hospital, Hong KongRecruiting
-
S&D Pharma SK s.r.o.UnknownCancer | Neutropenia | Febrile Neutropenia | Infection in an Immunocompromised HostSlovakia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedFever | Febrile NeutropeniaUnited States
-
Shanghai Jiao Tong University School of MedicineRecruiting
-
Kjeld SchmiegelowRecruitingPediatric Cancer | Neutropenia, FebrileDenmark
-
University Hospital, LilleMinistry of Health, FranceRecruiting
-
Hospital Infantil de Mexico Federico GomezHospital Juarez de Mexico; Instituto Nacional de PediatriaCompletedChemotherapy-Induced Febrile Neutropenia